CPRX
Catalyst Pharmaceuticals Inc

15,778
Mkt Cap
$2.84B
Volume
1.02M
52W High
$26.58
52W Low
$19.05
PE Ratio
13.79
CPRX Fundamentals
Price
$23.23
Prev Close
$23.39
Open
$23.54
50D MA
$23.91
Beta
1.02
Avg. Volume
1.29M
EPS (Annual)
$1.68
P/B
2.98
Rev/Employee
$3.24M
$2,263.82
Loading...
Loading...
News
all
press releases
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics
Catalyst Pharmaceuticals (NASDAQ:CPRX) highlighted continued growth in its rare disease portfolio and outlined efforts to expand patient identification and penetration for its lead product during a...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Cigna Stock Trades Below Industry P/E: Is It Worth Holding Now?
CI trades below industry P/E as Evernorth growth, steady earnings beats and buybacks support outlook, though rising medical costs and debt remain key risks.
Zacks·1d ago
News Placeholder
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
Zacks·2d ago
News Placeholder
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus
NKTR Q4 revenues and earnings beat estimates. The company focuses on rezpeg with phase III studies in atopic dermatitis planned for Q2 2026.
Zacks·2d ago
News Placeholder
Kennedy Capital Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. $CPRX
Kennedy Capital Management LLC lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 5.0% in the 3rd quarter, according to its most recent disclosure with the...
MarketBeat·2d ago
News Placeholder
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.
Zacks·2d ago
News Placeholder
RLMD Stock Surges 42% in a Week: Here's What You Should Know
Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a mid-stage bladder cancer study of NDV-01, simultaneously sharing phase III plans.
Zacks·3d ago
News Placeholder
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
Zacks·3d ago
News Placeholder
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data showing strong survival gains.
Zacks·4d ago
News Placeholder
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down
Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.
Zacks·4d ago
<
1
2
...
>

Latest CPRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.